Adalimumab, trade name Exemptia, is a potent TNF-inhibitor and anti-inflammatory drug manufactured and promoted by Zydus Cadila in India. Adalimumab works as anti-TNF, blocking over production of TNF and its harmful effects on the body. It's prescribed to people who have Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and to children having Juvenile Idiopathic Arthritis from a Rheumatologist. The usual dosage for Rheumatoid Arthritis is 40mg once in every 2 weeks.
Exemptia(adalimumab) has been researched, developed and produced by scientists at the Zydus Research Centre. The biosimilar is the first to be launched by any company in the world and is a 'fingerprint match' with the originator in terms of safety, purity and potency of the product. The biosimilar of Adalimumab is a part of Zydus' robust biologics programme which has the largest number of monoclonal antibodies under development in India. The group's R&D pipeline which comprises 15 biologics includes biosimilars and two novel biologics. These biologics are being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke.